New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:13 EDTLGNDLundbeck announces FDA acceptance of NDA submission for Carbamazepine IV
Captisol licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
08:03 EDTLGNDLigand sees Q4 EPS 57c-62c, consensus $67c
Subscribe for More Information
08:02 EDTLGNDLigand still sees FY14 EPS $1.50-$1.55, consensus $1.54
Subscribe for More Information
08:01 EDTLGNDLigand reports Q3 EPS 36c, consensus 31c
Subscribe for More Information
October 23, 2014
09:23 EDTLGNDLigand price target raised to $121.50 from $92 at Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use